NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

hyperopia, I noticed that you referenced me in this post.

ATLnsider has speculated that Northwest Bio is using poly-ICLC as a maturation and activation agent in the manufacturing process of DCVax-L and therefore, thinks it will be included in the marketing application. While I believe this manufacturing method may have been studied, I believe it was with DCVax-Direct, and not DCVax-L.

I wanted to correct and clarify my beliefs about DCVax-L and poly-ICLC. Here are my beliefs and opinions:

(1) I do not know for sure if poly-ICLC was included in the MAA filed with the MHRA.

(2) I hope poly-ICLC was included in the MAA filed with the MHRA, because more cancer patients will live longer, and more cancer patients will be effectively cured (5 of more years overall survival).

(3) After the 2010 clinical trial at UCLA proved that poly-ICLC was the best TLR agonist to use with DCVax-L (sometime around 2014), all current and future DCVax-L clinical trials have included DCVax-L along with poly-ICLC as the new control. There are no current clinical trials or future planned clinical trials, that do not include DCVax-L along with poly-ICLC.

(4) I am not aware of any clinical trials that have studied poly-ICLC with DCVax Direct. All of the completed trials, and future planned trials that I am aware of, are with DCVax-L along with poly-ICLC.

(5) The recently published peer-reviewed Nature study was of DCVax-L (ATL-DC) along with poly-ICLC.

However, I do believe there will be future basket trials with DCVax-L and DCVax Direct, along with poly-ICLC, that will test the efficacy and safety in treating multiple solid tumor cancers.